Cited by 3,445SARS-CoV-2 and COVID-19 ResearchRenin-Angiotensin System StudiesCOVID-19 Clinical Research Studies

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Open access
Kuba, Keiji, Imai, Yumiko, Rao, Shuan, Gao, Hong, Guo, Feng, Guan, Bin, Huan, Yi, Yang, Peng +16 more·2005·Nature Medicine

Abstract

During several months of 2003, a newly identified illness termed severe acute respiratory syndrome (SARS) spread rapidly through the world. A new coronavirus (SARS-CoV) was identified as the SARS pathogen, which triggered severe pneumonia and acute, often lethal, lung failure. Moreover, among infected individuals influenza such as the Spanish flu and the emergence of new respiratory disease viruses have caused high lethality resulting from acute lung failure. In cell lines, angiotensin-converting enzyme 2 (ACE2) has been identified as a potential SARS-CoV receptor. The high lethality of SARS-CoV infections, its enormous economic and social impact, fears of renewed outbreaks as well as the potential misuse of such viruses as biologic weapons make it paramount to understand the pathogenesis of SARS-CoV. Here we provide the first genetic proof that ACE2 is a crucial SARS-CoV receptor in vivo. SARS-CoV infections and the Spike protein of the SARS-CoV reduce ACE2 expression. Notably, injection of SARS-CoV Spike into mice worsens acute lung failure in vivo that can be attenuated by blocking the renin-angiotensin pathway. These results provide a molecular explanation why SARS-CoV infections cause severe and often lethal lung failure and suggest a rational therapy for SARS and possibly other respiratory disease viruses.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm1267

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 30 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., Bao, L., Zhang, B., Liu, G., Wang, Z., Chappell, M., Liu, Y., Zheng, D., Leibbrandt, A., Wada, T., Slutsky, A. S., Liu, D., Qin, C., Jiang, C., & Penninger, J. M.
Affiliations
  • Institute of Molecular Biotechnology (AT)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Wake Forest University Health Sciences (US)
  • St. Michael's Hospital (CA)
Corresponding author
Jiang, Chengyu
Venue
Nature Medicine
Published
2005-07-10
Volume
11
Issue
8
Pages
875-879
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2091671824
Cited by
3,445
References
30
Citations by year
2026: 28 · 2025: 55 · 2024: 136 · 2023: 223 · 2022: 391 · 2021: 875 · 2020: 1421 · 2019: 19 · 2018: 10 · 2017: 12 · 2016: 18 · 2015: 11 · 2014: 34 · 2013: 18 · 2012: 21
FWCI
22.04
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (30421003)
  • Österreichischen Akademie der Wissenschaften
  • Oesterreichische Nationalbank
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
angiotensin-converting enzyme 2, SARS-CoV, SARS, viral receptor, spike protein, acute lung injury, acute lung failure, renin-angiotensin system, viral pathogenesis, antiviral therapy, respiratory viruses
MeSH terms
Angiotensin-Converting Enzyme 2, Analysis of Variance, Animals, Carboxypeptidases, Immunohistochemistry, Peptidyl-Dipeptidase A, Lung Diseases, Membrane Glycoproteins, Viral Envelope Proteins, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Mice, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review